Quarterly ResultMay 15, 2026, 05:08 PM
Evofem Biosciences Q1 Net Loss $(5.47)M; Going Concern Doubt
AI Summary
Evofem Biosciences reported a net loss of $(5.47) million for Q1 2026, a significant decline from a net income of $0.96 million in Q1 2025, despite a slight increase in product sales to $0.899 million. The company faces substantial doubt about its ability to continue as a going concern due to ongoing operating losses, a $72.7 million working capital deficit, and a $902.9 million accumulated deficit. Management plans to address liquidity through increased revenue, licensing agreements, and additional funding, while also announcing a new distributorship agreement for SOLOSEC in sub-Saharan Africa.
Key Highlights
- Reported Q1 2026 net loss of $(5.47) million, compared to net income of $0.96 million in Q1 2025.
- Product sales increased slightly to $0.899 million in Q1 2026 from $0.845 million in Q1 2025.
- Operating expenses surged to $5.47 million in Q1 2026 from $0.52 million in Q1 2025.
- Company faces substantial doubt about its ability to continue as a going concern.
- Working capital deficit was $72.7 million and accumulated deficit reached $902.9 million as of March 31, 2026.
- Net cash provided by operating activities was $2.30 million in Q1 2026, up from $0.56 million in Q1 2025.
- Entered a distributorship agreement for SOLOSEC in sub-Saharan Africa in April 2026.
- Common Stock moved to OTCID on July 1, 2025, due to non-compliance with OTCQB bid price.
Price Impact
More from EVFM